

## **PROPECIA® 5-Year Multinational Study**

### **Fact sheet**

- Description:** The PROPECIA® 5-Year Multinational Study is a clinical trial to determine whether treatment with PROPECIA® (finasteride 1 mg) improves the outcome of male pattern hair loss (androgenetic alopecia) over the long term when compared with placebo.
- Investigators:** Conducted in 16 countries, including Canada, by 65 investigators including five Canadians.
- Objectives:** To assess the efficacy and safety of PROPECIA® compared with placebo in the treatment of male pattern hair loss (MPHL) over five years.
- Design:** An original one-year randomized, double-blind, placebo-controlled, multi-centre study was extended over four years.
- Results:** Treatment with PROPECIA® led to significant durable improvements in all endpoints compared to placebo ( $p \leq 0.001$ ); 65 per cent of patients experienced scalp hair growth and 90 per cent stopped the progression of hair loss.
- Conclusion:** The continued use of PROPECIA® over five years is well tolerated, significantly reduces hair loss progression and effectively restores hair growth in men with male pattern hair loss.

- 30 -

### **FOR MORE INFORMATION, PLEASE CONTACT:**

**Marlene Gauthier**  
Manager, Public Affairs  
Merck Frosst Canada Ltd.  
(514) 428-3057

**Mélanie Hould / Roch Landriault**  
NATIONAL *PharmaCom*  
(514) 843-2373 / 843-2345